UNC45B Inhibitors
UNC45B inhibitors encompass a range of compounds that modulate the activity of UNC45B, a protein crucial for myosin folding and assembly, as well as actin cytoskeleton regulation. Several chemicals, such as CK-666, CK-869, CK-548, CK-636, CK-666 analog, and CK-548 analog, indirectly inhibit UNC45B by targeting the Arp2/3 complex. These compounds disrupt actin filament nucleation, impacting UNC45B and, consequently, influencing cellular processes dependent on proper actin dynamics. Blebbistatin, Y-27632, and ML-7 are direct inhibitors of UNC45B. Blebbistatin disrupts myosin II function by inhibiting its ATPase activity, impacting UNC45B's role in myosin folding and assembly. Y-27632 and ML-7, on the other hand, target Rho-associated protein kinase (ROCK) and myosin light chain kinase (MLCK), respectively. By hindering actin-myosin interactions, these compounds directly modulate UNC45B activity, influencing cellular processes dependent on proper myosin function.
Latrunculin A, Cytochalasin D, SMIFH2, Jasplakinolide, and CK-636 indirectly inhibit UNC45B by perturbing actin dynamics. Latrunculin A disrupts actin polymerization, while Cytochalasin D interferes with actin filament assembly. SMIFH2 and CK-636 target the Arp2/3 complex, impacting actin filament nucleation. Jasplakinolide stabilizes actin filaments. All these compounds indirectly influence UNC45B, affecting cellular processes dependent on proper actin organization. In conclusion, UNC45B inhibitors exhibit diverse mechanisms, from targeting the Arp2/3 complex to modulating myosin function, providing valuable tools to study the intricate regulation of the actin cytoskeleton and myosin folding processes. Understanding these inhibitors' modes of action sheds light on strategies for conditions involving aberrant actin and myosin dynamics.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
CK 666 | 442633-00-3 | sc-361151 sc-361151A | 10 mg 50 mg | $315.00 $1020.00 | 5 | |
CK-666 inhibits UNC45B indirectly by targeting the Arp2/3 complex. As an Arp2/3 complex inhibitor, it disrupts actin filament nucleation, impacting UNC45B, which is involved in actin cytoskeleton regulation. This indirect inhibition modulates UNC45B activity, influencing cellular processes dependent on proper actin dynamics. | ||||||
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $179.00 $307.00 $455.00 $924.00 $1689.00 | 7 | |
Blebbistatin inhibits UNC45B by disrupting myosin II function. As a myosin II ATPase inhibitor, it hinders actin-myosin interactions, impacting UNC45B's role in myosin folding and assembly. This direct inhibition modulates UNC45B activity, influencing cellular processes dependent on proper myosin function. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $260.00 $799.00 | 36 | |
Latrunculin A indirectly inhibits UNC45B by disrupting actin dynamics. As an actin polymerization inhibitor, it prevents the formation of actin filaments, impacting UNC45B, which is involved in actin cytoskeleton regulation. This indirect inhibition modulates UNC45B activity, influencing cellular processes dependent on proper actin organization. | ||||||
CK-869 | 388592-44-7 | sc-507274 | 5 mg | $160.00 | ||
CK-869 inhibits UNC45B indirectly by targeting the Arp2/3 complex. As an Arp2/3 complex inhibitor, it disrupts actin filament nucleation, impacting UNC45B, which is involved in actin cytoskeleton regulation. This indirect inhibition modulates UNC45B activity, influencing cellular processes dependent on proper actin dynamics. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
Cytochalasin D indirectly inhibits UNC45B by disrupting actin dynamics. As an actin depolymerizing agent, it interferes with actin filament assembly, impacting UNC45B, which is involved in actin cytoskeleton regulation. This indirect inhibition modulates UNC45B activity, influencing cellular processes dependent on proper actin organization. | ||||||
SMIFH2 | 340316-62-3 | sc-507273 | 5 mg | $140.00 | ||
SMIFH2 inhibits UNC45B indirectly by targeting the Arp2/3 complex. As an Arp2/3 complex inhibitor, it disrupts actin filament nucleation, impacting UNC45B, which is involved in actin cytoskeleton regulation. This indirect inhibition modulates UNC45B activity, influencing cellular processes dependent on proper actin dynamics. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $180.00 $299.00 | 59 | |
Jasplakinolide indirectly inhibits UNC45B by stabilizing actin filaments. As an actin polymerization stabilizer, it enhances actin filament formation, impacting UNC45B, which is involved in actin cytoskeleton regulation. This indirect inhibition modulates UNC45B activity, influencing cellular processes dependent on proper actin organization. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 inhibits UNC45B by targeting Rho-associated protein kinase (ROCK). As a ROCK inhibitor, it hinders actin-myosin interactions, impacting UNC45B's role in myosin folding and assembly. This direct inhibition modulates UNC45B activity, influencing cellular processes dependent on proper myosin function. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
ML-7 inhibits UNC45B by targeting myosin light chain kinase (MLCK). As an MLCK inhibitor, it hinders actin-myosin interactions, impacting UNC45B's role in myosin folding and assembly. This direct inhibition modulates UNC45B activity, influencing cellular processes dependent on proper myosin function. | ||||||